ADL Amdl,

TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- (http://www.amdl.com/) AMDL, Inc., (AMEX:ADL) a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, announced that the AMDL-ELISA DR- 70(R) (FDP) test has been shown to be a useful test for the detection of cancer in clinical practice according to an independent study of 185 patients from the Medical Department II at the University Hospital in Frankfurt Germany. The results were published in the international medical research publication Alimentary Pharmacology & Therapeutics. The purpose of this independent study was to evaluate the potential of the DR-70 ELISA (FDP) test as a detection test for gastrointestinal cancers that include, colorectal, esophageal, gallbladder, gastric, liver, pancreatic and intestinal cancers. Additionally, the quantitative value of DR-70 (FDP) was tested as a parameter for the progression of these cancers. Serum samples were taken from a total of 80 cancer patients with histologically proven malignant tumors and 100 healthy blood donors in this study. Patients with colorectal cancer were also tested for carcinoembryogenic antigen (CEA), a competing diagnostic test to AMDL-ELISA DR-70 (FDP). The complete article about AMDL-ELISA DR-70 (FDP) can be accessed via AMDL's corporate website located at http://www.amdl.com/ under the RESOURCES link. "When we compared the DR-70 immunoassay with conventional tumor markers, DR-70 turned out to be superior to CEA in the detection of patients with colorectal cancer," according to the conclusion of authors. The authors also concluded that DR-70 (FDP) levels were shown to be significantly higher across all types of gastrointestinal cancers tested and not limited to specific tumor types, suggesting the AMDL-ELISA DR-70 (FDP) test could be clinically used as a global cancer detection tool. According to the results: -- The AMDL-ELISA DR-70 (FDP) test showed strong clinical performance with a sensitivity of 91% and a specificity of 93% in testing conducted on patients with hepatocellular, cholangiocellular, pancreatic, colorectal, stomach and oesophagus cancers. -- The test reliably differs between patients with cancer of the gastrointestinal tract or the hepatobilary system and healthy patients; therefore showing promise as a useful cancer detection tool in clinical practice. -- The study also found an association between the quantitative DR-70 value and the stage of the cancer in patients tested which suggests the AMDL-ELISA DR-70 (FDP) test can also be used as a prognostic factor in cancer monitoring. About AMDL: Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs approximately 320 people in the U.S. and China. The AMDL ELISA DR-70 (FDP) cancer diagnostic test was cleared to market by the US FDA on July 13, 2008 and the Company has 4 additional pharmaceutical and diagnostic products under review by various regulatory authorities. For additional information on AMDL and its products visit the company's website at http://www.amdl.com/ or call +1 (714)505-4460. AMDL Contact: Kristine Szarkowitz Director-Investor Relations (M) (206) 310-5323 (O) (206) 201-3286 DATASOURCE: AMDL, Inc. CONTACT: Kristine Szarkowitz, Director-Investor Relations of AMDL, Inc., mobile, +1-206-310-5323, office, +1-206-201-3286, Web site: http://www.amdl.com/

Copyright